Student Resources | Faculty, Postdoc, & Staff Resources
Search for:
Admin Login

Posts classified under: Neurology

Jeff Bronstein

Jeff Bronstein, M.D., Ph.D.

Biography

Jeff Bronstein received his bachelor’s degree from the University of California, Berkeley and M.D. and Ph.D. from UCLA as a recipient of the Medical Scientist Training Program Award. He completed a residency in Neurology and fellowship training in Movement Disorders at UCLA. Dr. Bronstein also completed a postdoctoral fellowship in molecular biology before being appointed an Assistant Professor of Neurology. He was later appointed Director of the Movement Disorders Program at UCLA. His interests and expertise include the management of Parkinson’s disease (PD) and other movement disorders, surgical treatment of PD, and developing new therapies for patients. Dr. Bronstein was recently awarded one of 6 National Parkinson’s Disease Centers at the Veterans Administration Medical Center with the goal of furthering research, education and clinical care in the Southwest US. His laboratory studies the cause of PD using cell models and a newly developed zebrafish model. His work supported by the NIH and private foundations. Dr. Bronstein also directs clinical trials in order to develop new therapies for PD that include transplantation and deep brain stimulation. He has received several awards and is widely published in the field.

Timothy F. Cloughesy, M.D.

Timothy Cloughesy, M.D.

Publications

A selected list of publications:

Bryant JA, Finn RS, Slamon DJ, Cloughesy TF, Charles AC   EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells Cancer biology & therapy. , 2004; 3(12): 1243-9.
Graham CA, Cloughesy TF   Brain tumor treatment: chemotherapy and other new developments Seminars in oncology nursing. , 2004; 20(4): 260-72.
Chang SM, Kuhn J, Wen P, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, Cloughesy T, De Angelis L, Razier J, Hess K, Dancey J, Prados MD   Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs Investigational new drugs. , 2004; 22(4): 427-35.
Puduvalli VK, Yung WK, Hess KR, Kuhn JG, Groves MD, Levin VA, Zwiebel J, Chang SM, Cloughesy TF, Junck L, Wen P, Lieberman F, Conrad CA, Gilbert MR, Meyers CA, Liu V, Mehta MP, Nicholas MK, Prados M   Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study Journal of clinical oncology : official journal of the American Society of Clinical Oncology. , 2004; 22(21): 4282-9.
Mischel PS, Cloughesy TF, Nelson SF   DNA-microarray analysis of brain cancer: molecular classification for therapy Nature reviews. Neuroscience. , 2004; 5(10): 782-92.
Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, Liau LM, Mischel PS, Nelson SF   Gene expression profiling of gliomas strongly predicts survival Cancer research. , 2004; 64(18): 6503-10.
Kaleita TA, Wellisch DK, Cloughesy TF, Ford JM, Freeman D, Belin TR, Goldman J   Prediction of neurocognitive outcome in adult brain tumor patients Journal of neuro-oncology. , 2004; 67(1-2): 245-53.
Wang Y, Zhu S, Cloughesy TF, Liau LM, Mischel PS   p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition Oncogene. , 2004; 23(6): 1283-90.
Parker RJ, Fruehauf JP, Mehta R, Filka E, Cloughesy T   A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma Journal of neuro-oncology. , 2004; 66(3): 365-75.
Prados MD, Yung WK, Jaeckle KA, Robins HI, Mehta MP, Fine HA, Wen PY, Cloughesy TF, Chang SM, Nicholas MK, Schiff D, Greenberg HS, Junck L, Fink KL, Hess KR, Kuhn J   Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study Neuro-oncology. , 2004; 6(1): 44-54.
Lu KV, Jong KA, Rajasekaran AK, Cloughesy TF, Mischel PS   Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line Laboratory investigation; a journal of technical methods and pathology. , 2004; 84(1): 8-20.
Shai R, Shi T, Kremen TJ, Horvath S, Liau LM, Cloughesy TF, Mischel PS, Nelson SF   Gene expression profiling identifies molecular subtypes of gliomas Oncogene. , 2003; 22(31): 4918-23.
Mischel PS, Nelson SF, Cloughesy TF   Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy Cancer biology & therapy. , 2003; 2(3): 242-7.
Brown PD, Wald JT, McDermott MW, Baumann GS, Cloughesy TF   Oncodiagnosis panel: 2002. Metastatic NSCLC Radiographics : a review publication of the Radiological Society of North America, Inc. , 2003; 23(6): 1591-611.
Brown PD, Wald JT, McDermott MW, Baumann GS, Cloughesy TF   Oncodiagnosis panel: 2002. Optic nerve glioma or optic nerve meningioma Radiographics, 2003; 23(6): 1591-611.
Brown PD, Wald JT, McDermott MW, Baumann GS, Cloughesy TF   Oncodiagnosis panel: 2002. Patient’s symptoms not related to the lesion seen in the MR images Radiographics, 2003; 23(6): 1591-611.
Brown PD, Wald JT, McDermott MW, Baumann GS, Cloughesy TF   Oncodiagnosis panel: 2002. Primary glial neoplasm or less likely an intracranial abscess Radiographics : a review publication of the Radiological Society of North America, Inc. , 2003; 23(6): 1591-611.
Jaeckle KA, Hess KR, Yung WK, Greenberg H, Fine H, Schiff D, Pollack IF, Kuhn J, Fink K, Mehta M, Cloughesy T, Nicholas MK, Chang S, Prados M   Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study Journal of clinical oncology : official journal of the American Society of Clinical Oncology. , 2003; 21(12): 2305-11.
Mischel PS, Cloughesy TF   Targeted molecular therapy of GBM Brain Pathol, 2003; 13(1): 52-61.
Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL, Mischel PS   Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo Cancer research. , 2003; 63(11): 2742-6.
Cloughesy TF, Filka E, Kuhn J, Nelson G, Kabbinavar F, Friedman H, Miller LL, Elfring GL   Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen Cancer. , 2003; 97(9 Suppl): 2381-6.
Mischel PS, Shai R, Shi T, Horvath S, Lu KV, Choe G, Seligson D, Kremen TJ, Palotie A, Liau LM, Cloughesy TF, Nelson SF   Identification of molecular subtypes of glioblastoma by gene expression profiling Oncogene. , 2003; 22(15): 2361-73.
1 2 3 4 5 … 13